Bismuth potassium citrate

• UNSPSC Description:

  Bismuth potassium citrate (Bismuth tripotassium dicitrate) is an orally active gastric mucosal protector and has antibacterial and anti-inflammatory activity. Bismuth potassium citrate relieves stomach pain, resists H. pylori growth and repairs gastric mucosa. Bismuth potassium citrate combined with Omeprazole (HY-B0113) has a safe and high efficacy against H. pylori infection, which is promising for research of peptic ulcers, gastric cancer and tubulointerstitial nephritis[1][2][3][4][5][6].

• Target Antigen:

  Bacterial

• Type:

  Reference compound

• Related Pathways:

  Anti-infection

• Field of Research:

  Cancer; Infection; Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/bismuth-potassium-citrate.html

• Purity:

  98.0

• Solubility:

  H2O : 100 mg/mL (ultrasonic)

• Smiles:

  O=C(CC(C([O-])=O)(O)CC([O-])=O)[O-].O=C(CC(C([O-])=O)(O)CC([O-])=O)[O-].[K+].[K+].[K+].[Bi+3]

• Molecular Weight:

  704.47

• References & Citations:

  [1]Luo HY, et al. Pharmacokinetic and Safety Study of Bismuth Potassium Citrate Formulations in Healthy Subjects[J]. Drugs R D. 2024 Mar;24(1):81-87.|[2]JIANG J X. Efficacy of compound bismuth potassium citrate capsules combined with omeprazole in eradication of Helicobacter pylori infection: A clinical study[J]. Academic Journal of Second Military Medical University, 2010: 973-977.|[3]Mikhailova M, et al. BISMUT-INDUCED ONSET OF ACUTE TUBULOINTERSTICIAL NEPHRITIS: A CLINICAL CASE[J].|[4]Naidenko E S, et al. Obtaining bismuth-potassium citrate[J]. Chemistry for Sustainable Development, 2012, 20: 523-528.|[5]Xuan Y, et al. High-security multifunctional nano-bismuth-sphere-cluster prepared from oral gastric drug for ct/pa dual-mode imaging and chemo-photothermal combined therapy in vivo[J]. Advanced Functional Materials, 2019, 29(18): 1900017.|[6]S M Hinsull, et al. Effect of colloidal bismuth subcitrate on age related gastric lesions in the rat. Gut. 1991 Apr;32(4):355-60. doi: 10.1136/gut.32.4.355.J Virol. 2023 Jun 22;e0051223.|Adv Sci (Weinh). 2024 Oct 30:e2408707.|Carbohydr Polym. 2024 Dec 15:346:122645.|Exp Cell Res. 2020 Aug 1;393(1):112054.|Heliyon. 2024 Jan 17.|J Ethnopharmacol. 2024 Jan 12:117759.|J Mol Med (Berl). 2019 Aug;97(8):1183-1193.|J Nanobiotechnology. 2023 Oct 19;21(1):383.|Nat Commun. 2024 Sep 10;15(1):7923.|Nature. 2023 Jun;618(7964):374-382.|Phytother Res. 2024 Mar 25.|SSRN. 2024 Mar 20.|Theranostics. 2020 Jul 25;10(21):9477-9494. |Bioengineered. 2021 Dec;12(2):11610-11621.|Biol Trace Elem Res. 2023 May 8.|Biomed Pharmacother. 2023 Aug 18;166:115333.|Drug Des Devel Ther. 2024 Feb 1:18:259-275.|Front Immunol. 2024 Oct 1:15:1397727.|Front Mol Biosci. 22 July 2022.|Int J Biol Sci. 2024 Aug 6;20(11):4222-4237.|Oxid Med Cell Longev. 2022 Apr 25;2022:3846217.|Research Square Preprint. 2021 Jul.|Food Chem. 2022: 134807.|Nature. 2024 Dec 18.|New J Chem. 03 Aug 2022.|Insect Biochem Mol Biol. 2023 May 12;103958.|Regen Biomater. 2024 Aug 22:11:rbae098.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, sealed storage, away from moisture)

• Clinical Information:

  Launched

• CAS Number:

  57644-54-9